Clinical trials Below are current clinical trials.85 studies in Gastroenterology and Hepatology (open studies only). Filter this list of studies by location, status and more. A Study to Better Understand Why Patients Gain Weight After Undergoing Liver Transplantation Rochester, Minn. The purpose of this study is to understanding the mechanisms of weight gain in patients following liver transplantation, action, and indicate approaches to prevent weight gain. Early pancreatic cancer detection Jacksonville, Fla. The primary purpose of this study is to standardize the collection of demographic, clinical, and imaging data, and biosamples for a large high-risk familial Pancreatic Ductal Adenocarinoma (PDAC) cohort at consortium clinical cancer centers, worldwide. A Study to Assess Cisplatin and Combination Chemotherapy in Treating Children and Young Adults with Hepatoblastoma or Liver Cancer After Surgery Rochester, Minn. The purpose of this study is to determine how well cisplatin and combination chemotherapy works in treating children and young adults with hepatoblastoma or liver cancer after surgery. Drugs used in chemotherapy, such as cisplatin, doxorubicin, fluorouracil, vincristine sulfate, carboplatin, etoposide, irinotecan, sorafenib, gemcitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving combination chemotherapy after surgery may kill more tumor cells. An Expansion Study to Evaluate Dose Escalation, Safety and Tolerability of SAR444881 in Patients with Advanced Solid Tumors Rochester, Minn., Scottsdale/Phoenix, Ariz. The purpose of this study is to evaluate the safety, tolerability, and preliminary anti-tumor activity of SAR444881 alone and in combination with pembrolizumab or with cetuximab. The study will enroll advanced cancer patients with unresectable or metastatic disease who are refractory to or are not candidates for standard approved therapy and will be comprised of two parts - an initial "3 + 3" dose escalation phase (Part 1) with Sub-Parts 1A (monotherapy SAR444881), 1B (SAR444881 in combination with pembrolizumab) and 1C (SAR444881 in combination with cetuximab) followed by a dose optimization/expansion phase (Part 2), including Sub-Part 2A (Dose Optimization) with Cohorts A1 (SAR444881 in combination with pembrolizumab, carboplatin, and pemetrexed), A2 (SAR444881 in combination with pembrolizumab), B1 (SAR444881 in combination with pembrolizumab and later therapy), and C1 (SAR444881 in combination with cetuximab and later therapy), as well as Sub-Part 2B (Dose Expansion) with Cohort D1 (monotherapy SAR444881). A Study to Evaluate the Effectiveness and Safety of PRV-015 in Adult Patients wth Non-responsive Celiac Disease as an Adjunct to a Gluten-free Diet Rochester, Minn. The purpose of this study is to evaluate the effectiveness and safety of PRV-015 in adult patients with non-responsive celiac disease (NRCD) who are on a gluten-free diet (GFD). A Study to Evaluate the Effect of Improving Glycemic Control on Gastric Emptying in Type 1 and Type 2 Diabetes Mellitus Rochester, Minn. The purpose of this study is to evaluate the effects of improving glycemic control, and/or reducing glycemic variability on gastric emptying, intestinal barrier function, autonomic nerve functions, and epigenetic changes in subjects with type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) who are switched to intensive insulin therapy as part of clinical practice. A Study to Create a Registry for Patients at High-Risk for Pancreatic Cancer Rochester, Minn. This study aims to facilitate discovery and validation of tests for early detection in subjects at high risk for pancreatic ductal adenocarcinoma (PDAC). and to facilitate the use of state-of-the-art machine learning-based algorithms that utilize databases and images with the purpose of identifying early stages of pancreatic cancer, as well as people at high-risk.The study also aims to provide a platform for development of an interventional protocol for early detection of PDAC. A Study to Evaluate if New Tests (“biomarkers”) of Blood, Stool, Pancreas Cyst Fluid, or Pancreas Juice can be Used to Diagnose Malignant or Pre-malignant Changes in People with Pancreas Cysts Rochester, Minn. The goal of this protocol is to collect biospecimens in order to prospectively evaluate diagnostic and prognostic performance of MDMs for detection of advanced neoplasia in pancreatic cysts. A Study to Evaluate the Use of Confocal Laser Endomicroscopy as an IMaging Biomarker (CLIMB Study) for the Diagnosis of Pancreatic Cystic Lesions Scottsdale/Phoenix, Ariz. The purpose of this study is to evaluate EUS-nCLE as an imaging biomarker and PCL fluid DNA analysis as a molecular biomarker for the management of pancreatic cystic lesions (PCLs). A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz. The purpose of this study is to compare the effectiveness of RO7198457 versus watchful waiting in patients with circulating tumor DNA (ctDNA) positive, surgically resected Stage II/III rectal cancer, or Stage II (high risk)/Stage III colon cancer. Pagination Clinical studies PrevPrevious Page Go to page 33 Go to page 44 Go to page 55 Go to page 66 Go to page 77 NextNext Page Request an appointment Expertise & rankingsResearch Nov. 07, 2024 Share on: FacebookTwitter Mayo Clinic in Rochester, Minnesota, has been recognized as the best Gastroenterology & GI Surgery hospital in the nation for 2024-2025 by U.S. News & World Report. Learn more about this top honor Gastroenterology and HepatologyDepartmenthomeSectionsOverviewTests & proceduresConditions treatedDoctorsDoctors by location and specialtySpecialty groupsExpertise & rankingsClinical trialsResearchPatient storiesCosts & insuranceNews from Mayo ClinicReferrals Research: It's all about patients Show transcript for video Research: It's all about patients [MUSIC PLAYING] Joseph Sirven, M.D., Professor of Neurology, Mayo Clinic: Mayo's mission is about the patient. The patient comes first. So the mission and research here is to advance how we can best help the patient, how to make sure the patient comes first in care. So in many ways, it's a cycle. It can start with as simple as an idea worked on in a laboratory, brought to the patient bedside, and if everything goes right — and let's say it's helpful or beneficial — then brought on as a standard approach. And I think that is one of the unique characteristics of Mayo's approach to research — that patient-centeredness — that really helps to put it in its own spotlight. SectionsRequest an AppointmentOverviewTests & proceduresConditions treatedDoctorsDoctors by location and specialtySpecialty groupsExpertise & rankingsClinical trialsResearchPatient storiesCosts & insuranceNews from Mayo ClinicReferrals ORG-20308333 Medical Departments & Centers Gastroenterology and Hepatology